Figure 1: ()   The production of therapeutic proteins like monoclonal antibodies (MAbs) and bispecifics depends on mammalian expression due to the posttranslational modifications occurring in these molecules. At Boehringer-Ingelheims (BIs) BioXcellence unit, we use the BI-HEXâ„¢ mammalian expression platform for fast and cost-efficient development of high-titered manufacturing processes. The BI-HEXâ„¢ platform is composed of the following interlinked elements: BI’s proprietary vector system, the BI-HEXâ„¢ cell lines, which are derived from the CHO-DG44 cell line (1), a short…